Lanean...
An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years
New molecular mechanisms that can be targeted with specific drugs have recently emerged for the treatment of systemic sclerosis (SSc) patients. Over the past 3 years, the achievement of one large phase 3 trial has led to the approval by drug agencies of the first drug licenced for SSc-related inters...
Gorde:
| Argitaratua izan da: | Arthritis Res Ther |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BioMed Central
2021
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8168022/ https://ncbi.nlm.nih.gov/pubmed/34074331 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-021-02536-5 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|